AMP Heart Failure

Home
Our Programs
Accelerating Medicines Partnership® (AMP®)
AMP Heart Failure

Our mission is to use deep phenotyping to advance precision therapies for patients with heart failure with preserved ejection fraction (HFpEF).

The Accelerating Medicines Partnership® Heart Failure Program (AMP® HF) is focused on a major unmet need in cardiovascular health. AMP HF brings together partners from the public, private, and nonprofit sectors to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF), which continues to stymie researchers and clinicians. Using cutting-edge technologies, including digital measurements and artificial intelligence analytic methods, AMP HF aims to change the landscape of heart failure treatment paradigms through refinement of HFpEF classification and discovery of improved, more precise treatment options, thus improving the outlook for millions of patients around the world.

Goals

Identify potential subtypes/endotypes of HFpEF for prospective validation, refinement, and extension.
Create a cohort and database of HFpEF patients, comparators, and matched controls with baseline and longitudinal follow-up electronic health record, clinical, imaging and omics data, and biospecimens.
Validate and refine the “clinically actionable” endotypes of HFpEF identified from the extant datasets.
Leverage endotype data to develop analytical plans for the identification of novel therapeutic targets.
Develop the framework and master protocol for testing the precision therapeutic against the identified targets for each HFpEF endotype.

Learn More

Limited Treatment Options

Difficulties in finding effective therapies for HFpEF patients have been attributed to the current approach of “bundling” diverse clinical phenotypes under a single diagnosis. Cardiovascular disease experts are increasingly urging changes to the HFpEF disease definition that would classify the disease based on distinct pathologic and physiologic systems. Modern phenotyping technologies have the potential to refine the diagnostic approach to HFpEF diagnosis so critical to both defining patient endotypes and the development of targeted therapies.

Coordinated Research Strategy

The development of new therapies for HFpEF patients requires a coordinated strategy that engages patients, clinicians, researchers, regulators, and industry. AMP HF will advance our knowledge of HFpEF using two complementary, integrated research components: 1) retrospectively analyze existing HFpEF patient datasets, sourced from both public and private sector funded studies followed by 2) confirmation of the retrospective study findings in an observational cohort, laying the groundwork for development of new precision treatments.

Partners

Private Sector Partners

Public Sector Partners

Moving data science and healthcare forward is at the heart of everything we do at the American Heart Association. The American Heart Association is excited to support the AMP HF program as it brings technology and research together to work toward improved care for heart failure patients.

-Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer, American Heart Association

Ionis is proud to participate in the Accelerating Medicines Partnership. At Ionis, we know that sick people depend on us. We have a rich history of working closely with academic and industry partners to advance the understanding of complex diseases and develop precision medicine therapies. We are excited to contribute to this public-private partnership and do the same for heart failure with preserved ejection fraction (HFpEF).

- Adam Mullick, Ph.D., Vice President, Drug Discovery and Cardiovascular Franchise Research Leader, Ionis Pharmaceuticals, Inc.

Read What Our Partners Are Saying

Data Portals

AMP Heart Failure Knowledge Portal

The AMP HF Knowledge Portal will provide access to both existing and new data, analytical tools, and other resources to support the study of heart failure with preserved ejection fraction (HFpEF).

Learn More